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ABSTRACT: We analyzed more than 1 million small
molecules with the goal of finding simple synthetic compounds
that potently inhibit cancer cell growth. We identified three such
compounds with unknown mechanisms of action. Subsequent
studies revealed that all three of these small molecules target
microtubules. These three scaffolds can serve as templates for
developing new microtubule-targeted agents, overcoming the
limits of existing microtubule-inhibiting drugs derived from
complex natural products.
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O
ne potential benefit of using small molecules for studying
biological processes is the possibility of obtaining leads
for further drug development efforts. Typically, small molecules
in large libraries are selected for druglike properties through
computational filters. Nonetheless, even with the best filters,
many hits from screens lack druglike properties.
1 Such
compounds may contain reactive groups, have poor water
solubility, or have low potency. Compounds with such liabilities
may lead to identification of novel target proteins, which may in
turn provide a starting point to create more druglike scaffolds
acting through the same targets.
In some cases, high potency can compensate for lack of other
druglike properties. Natural products such as paclitaxel and
vinblastine are clinically used anticancer drugs with high
molecular weights and poor water solubility; these drugs
require complex formulations to be used clinically, which limits
their bioavailability and ultimate clinical efficacy.
In oncology, where the rate of successful drug development
is less than 5%, a major reason for drug attrition is lack of
clinical efficacy, which has a strong correlation with drug
potency.
2 The NCI DTP performed a retrospective analysis of
2306 compounds submitted for NCI60 testing and found a
striking correlation between potency and subsequent in vivo
activity, which indicates that compounds with high potency are
expected to result in good efficacy in later stages of drug
development.
3
In an effort to find small molecule anticancer drug candidates
with high potency, we generated and analyzed cell-based
screening data using more than 1 million compounds and
selected lethal compounds with the highest potency. We then
selected only those high potency compounds with simple
synthetic structures for further analysis, leading to three novel
compounds. We used the NCI60 platform to elucidate the
mechanism of action of these three compounds as microtubule
inhibitors; they have potential benefits as drug leads for cancer
chemotherapy.
We screened compounds for growth inhibitory activity in
engineered tumorigenic cell lines, including BJeLR cells.
4,5
BJeLR cells are derived from human skin tissue and were
engineered to express the catalytic subunit of human
telomerase (hTERT), the SV40 large T and small T antigens
(LT and ST), and an oncogenic allele of HRAS (HRASG12V).
We found that the number of lethal compounds with high
potency was small, which led us to conclude that potency of
lethal compounds alone can be a stringent selection criterion in
cell-based assays.
For example, we were able to identify only 29 compounds
out of >1 million compounds tested that had EC50 values less
than 100 nM for growth inhibition (see Figure S1 in the
Supporting Information). To deduce the molecular mechanism
of these highly potent compounds, we grouped them based on
their structures and classified them according to their known
target proteins (Table 1).
The structural information on each compound and dose−
response curves for viability are presented in Figure S1 in the
Supporting Information. Microtubule inhibitors were the most
common type of mechanism, representing more than 68% of
the total. Translation inhibition, nonspecific kinase inhibition,
transcription inhibition, a nucleotide mimicry, and top-
oisomerase II inhibition were additional mechanisms identified.
We also discovered three novel compounds whose biological
activities had not been studied. We examined the structures of
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represented distinct scaffolds (Figure 1). New batches of
compounds were purchased, and the authenticity of each
compound was determined using MS and NMR analysis (see
Figure S3 in the Supporting Information). The compounds
were tested in three different cell lines that were used in the
original screening to confirm their activities (Figure 1). The
activity of each compound was reproducible in these cell lines,
albeit with varying potency. Compound 1 is built around a 4-
chromone ring system, compound 2 contains a triazolothiadia-
zine system, and compound 3 contains oxazole and
sulfonamide groups. We were interested in all three compounds
because they reproducibly inhibited the growth of cancer cell
lines with less than 100 nM EC50 values (Figure 1), and they
were all relatively simple synthetic compounds.
We could not deduce a specific mechanism based on their
structures, so we decided to submit these compounds to the
NCI DTP for NCI60 testing, in which each compound's
growth inhibitory activity is examined across 60 different cancer
cell lines derived from different tissues of origins.
6 A sensitivity
profile across the 60 cancer cell lines was obtained, which can
be used as a seed to find compounds with similar sensitivity
profiles within NCI's database, using the algorithm known as
COMPARE.
7 If the pattern of sensitivity in the 60 cell lines is
similar to any known cytotoxic compound, it is likely that these
two compounds have common targets or mechanisms for
inducing cell death or growth inhibition. For example, the
Yamori group successfully identified the mechanism of a PI3K
inhibitor using this approach.
8 When we analyzed the sensitivity
profile of these compounds with COMPARE, we found
microtubule inhibitors were the top-ranked compounds,
suggesting that these novel compounds might also be
microtubule-targeting compounds (Table 2).
To test the hypothesis generated by the COMPARE analysis,
we used an antitubulin antibody to stain cellular microtubules
and examined changes in microtubule dynamics upon
compound treatment. As shown in Figure 2A, a hairlike
microtubule network was visualized upon immunofluorescence
staining of control HT-1080 cells. However, this microtubule
network disappeared when inhibitors of microtubule polymer-
ization (colchicine or vinblastine) were added to HT-1080 cells
(Figure 2A).
Cells treated with 2 and 3 also lost their microtubule network
in a manner similar to vinblastine-treated cells, confirming the
microtubule-targeting activity of these two compounds (Figure
2A). In contrast, cells treated with 1 retained their microtubule
network, albeit with a shortened length. This pattern was
similar to what was reported in paclitaxel-treated cells.
9
The effects of these compounds on tubulin polymerization
were further examined in an in vitro assay using purified
porcine brain tubulin.
10 In this assay, tubulin monomer was
self-polymerized to microtubules under buffered conditions,
increasing light scattering at 340 nm. Microtubule-depolyme-
rizing drugs, such as vinblastine and colchicine, are known to
inhibit self-polymerization activity of tubulin in this assay.
When we added vinblastine to the reaction mixture, it inhibited
self-polymerization, as expected (Figure 2B). Compound 3 also
inhibited self-polymerization of tubulin monomers, implying
that it directly binds to tubulin and induces depolymerization of
microtubule network within cells (Figure 2B).
On the other hand, paclitaxel, a microtubule-stabilizing agent,
accelerated polymerization, showing faster kinetics than
untreated controls (Figure 2B). Compound 1 displayed similar,
faster kinetics in the microtubule reconstitution experiment,
indicating that it binds and stabilizes the microtubule network,
as paclitaxel does. The kinetics of 2-treated samples were
complex; they did not show a clear stabilization or
destabilization effect on microtubule formation, although
immunocytochemistry clearly demonstrated a microtubule-
Table 1. Grouping of Highly Potent Lethal Compounds
Based on Their Structures and Known Activities
known bioactivity no. of compds
microtubule inhibitor 20
translation inhibitor 2
kinase inhibitor 1
transcription inhibitor 1
nucleotide analog 1
topoisomerase II inhibitor 1
unknown 3
total 29
Figure 1. Confirmation of growth inhibitory activity in three different
cell lines. HT-1080 and BJeLR cells are derived from human
fibroblasts; MCF10A cells are derived from a breast tissue.
Table 2. Analysis of the NCI60 Database Using the
COMPARE Algorithm
a
rank correlation compd biological target
seed: 1(CID4970947)
1 0.636 paclitaxel (Taxol) microtubule
2 0.62 maytansine microtubule
3 0.581 S-trityl-L-cysteine KIF11(EG5)
seed: 2(CID663143)
1 0.713 maytansine microtubule
2 0.698 vinblastine sulfate microtubule
3 0.684 rhizoxin microtubule
seed: 3(CID20959075)
1 0.808 maytansine microtubule
2 0.754 vinblastine sulfate microtubule
3 0.682 rhizoxin microtubule
aThe sensitivity profile of each hit compound was used as a seed for
COMPARE analysis. Each table lists the top three ranked compounds
that showed the most similar pattern to the sensitivity profile of each
hit compound using the NCI's database. KIF11 is a microtubule-
binding protein.
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targets microtubule-associated proteins, not tubulin itself, to
inhibit the polymerization process within cells, as exemplified
by S-trityl-L-cysteine, a KIF11 targeting compound (Table 2).
We then investigated the cell death pathways that were
activated upon compound treatment. It has been reported that
microtubule-disrupting agents activate the cellular apoptotic
machinery to kill cancer cells.
11,12 Indeed, we observed dose-
and time-dependent activation of cellular caspases after
treatment with each of these three compounds (Figure S2A
in the Supporting Information).
However, we found that caspase activation only partially
contributed to the cell death, as two different caspase inhibitors,
z-VAD-fmk and Boc-D-fmk, showed small inhibitory effects on
the compounds' efficacy but no effect on potency (Figure S2B
in the Supporting Information). This observation led us to
explore additional cell death modulators to find key
mechanisms regulating cell death induced by microtubule
inhibitors. Accordingly, we tested 32 chemical and genetic
perturbations to cell death for their effects on the sensitivity of
tumor cells to these microtubule inhibitors (Table S1 in the
Supporting Information). These cell death modulators were
selected based on previous studies on validated suppressors and
sensitizers of various forms of cell death. We confirmed the cell
death modulating activity of the chemicals and genetic materials
in our previous report.
13 Vinblastine and colchicine were
included in the analysis in parallel to see if there are cell death
modulators common to microtubule-targeting agents. This
analysis revealed several cell death modulators that showed
stronger effects than caspase inhibitors in this experimental
setting (Figure 3).
These modulators are an iron chelator (deferoxamine), a
calpain inhibitor (ALLN), and a calcium channel blocker
(Co2+). The interaction between paclitaxel and calpain
inhibitors was reported by Wang et al.
14 In the paper, the
authors concluded that a calpain inhibitor could ameliorate
paclitaxel-induced sensory neuropathy in a mouse model, which
is consistent with the data that we have obtained. On the other
hand, several calcium channel blockers have been used as
chemosensitizers for MTIs,
15−17 which is contradictory to our
observation. The mechanism of chemosensitization is known to
be an off-target effect of some calcium channel blockers on
competitive inhibition of the multiple drug resistance (MDR)
gene product. It is possible that, unlike other calcium channel
blockers, Co2+ does not inhibit MDR, leading to the protective
effect in our assay. The effect of iron chelation was particularly
striking. Further efforts to improve the efficacy of microtubule
inhibitors could be directed toward these mechanisms (Figure
3).
The results of this modulator screening using small
molecules and genetic reagents are significant, because they
raise questions about the mechanism of cell death induced by
microtubule-targeting agents, which may illuminate mecha-
nisms of drug resistance to such agents. Three main causes of
drug resistance are known for microtubule-targeting agents:
drug efflux by ATP binding cassette (ABC) family membrane
transporters,
18 quantitative or qualitative alterations in micro-
tubules,
19 and deficiency in apoptotic processes.
20 Our
modulator screening results suggest that calcium channels,
calpain, and iron metabolism are additional factors related to
MTI drug resistance.
There are eight MTIs currently in clinical use; vinblastine,
docetaxel, vinorelbine tartrate, ixabepilone, vincristine sulfate,
halaven, colchicine, navelbine, and cabazitaxel. All of these
compounds are natural product derivatives violating Lipinski's
rule of 5, with the exception of colchicine. Although these drugs
are in the mainstream in chemotherapy regimens, their poor
solubility, synthetic tractability, and serious side effects are still
problematic. Antitumor agents derived from synthetic small
molecules, such as the compounds reported here, may
overcome the liabilities of current MTIs.
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Figure 2. Microtubule network is the target for 1−3. (A)
Immunocytochemistry confirmed alteration of microtubule dynamics
after compound treatment. (B) An in vitro microtubule polymer-
ization assay revealed that 3 is a microtubule-destabilizing agent,
whereas 1 is a microtubule-stabilizing agent. It is likely that 2 targets a
microtubule-regulating protein, not microtubules themselves. Com-
pounds were tested at 5 μM.
Figure 3. Suppressor screening of MTI-induced cell death. The heat
map shows changes in the sensitivity of HT-1080 cells to MTI-induced
cell death in the presence of known cell death modulators. See the
Supporting Information for methods in detail.
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